Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients

References

• Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase iii children’s oncology group trial AAML0531. J Clin Oncol. 2014;32(27):3021–3032.
   Web of Science ®Google Scholar
• Gibson BE, Webb DK, Howman AJ,WKUKCLWG and the DCOG, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155:366–376.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122:37–43.
   PubMed Web of Science ®Google Scholar
• Imamura T, Iwamoto S, Kanai R, Oda M ASJA of CLS, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003–06 from the Japan association of childhood leukaemia study. Br J Haematol. 2012;159:204–210.
   PubMed Web of Science ®Google Scholar
• Reedijk AMJ, Klein K, Coebergh J, et al. Improved survival for children and young adolescents with acute myeloid leukemia : a Dutch study on incidence, survival and mortality. Leukemia. 2019;33:1349–1359.
   PubMed Web of Science ®Google Scholar
• Creutzig U, van den Heuvel-eibrink MM, Gibson B, et al. Kaspers GJ RDAC of the IBSG. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–3205.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119:5980–5988.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949–2962.
   PubMed Web of Science ®Google Scholar
• Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110:3532–3539.
   PubMed Web of Science ®Google Scholar
• Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the tenth medical research council acute myeloid leukaemia trial (MRC AML10). Br J Haematol. 1999;106:436–444.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18:72–77.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Hassler A, Perner C, et al. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J. 2016;6:e382.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35:2082–2094.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol. 2009;147:125–128.
   PubMed Web of Science ®Google Scholar
• Lewis V, Yanofsky R, Mitchell D, et al. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Pediatr Infect Dis J. 2014;33:126–129.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Young JA WJIDS of A, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance : summary of the 2011 4 th european conference on infections in Leukemia. Haematologica. 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Motta I, Audisio E, et al. Di Perri G MF. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis. 2013;13:563.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Walsh TJ. Prophylactic measures during induction for acute myeloid leukemia. Curr Oncol Rep [Internet]. 2017;19:1–10. [cited 2019 Mar 5]. Available from: http://link.springer.com/10.1007/s11912-017-0574-9
   PubMed Web of Science ®Google Scholar
• Sung L, Phillips R, Lehrnbecher T, Cancer TL-EJ of, et al. Time for paediatric febrile neutropenia guidelines–children are not little adults. Eur J Cancer. 2011;47:811–813.
   PubMed Web of Science ®Google Scholar
• Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol. 1997;99:580–588.
   PubMed Web of Science ®Google Scholar
• Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. J Clin Pharmacol. 2016;56:1060–1075.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Schutze GE. The use of systemic and topical fluoroquinolones. Pediatrics. 2016;138:e20162706.
   PubMed Web of Science ®Google Scholar
• Inaba H, Gaur AH, Cao X, et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer. 2014;120:1985–1992.
   PubMed Web of Science ®Google Scholar
• Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113:376–382.
   PubMed Web of Science ®Google Scholar
• Nolt D, Lindemulder S, Meyrowitz J, et al. Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML). Pediatr Blood Cancer. 2015;62:1149–1154.
   PubMed Web of Science ®Google Scholar
• Yeh TC, Liu HC, Hou JY, et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer. 2014;120:1255–1262.
   PubMed Web of Science ®Google Scholar
• Felsenstein S, Orgel E, Rushing T, et al. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. Pediatr Infect Dis J. 2015;34:e78–84.
   PubMed Web of Science ®Google Scholar
• Al Omar S, Anabtawi N, Al Qasem W, et al. Bacterial infections in children with acute myeloid leukemia receiving ciprofloxacin prophylaxis. J Pediatr Hematol Oncol. 2017;39:e131–e135.
   PubMed Web of Science ®Google Scholar
• Sun Y, Huskey R, Tang L, et al. Adverse effects of intravenous vancomycin-based prophylaxis during therapy for pediatric acute myeloid leukemia. Antimicrob Agents Chemother. 2018;62:e01838–17.
   PubMed Web of Science ®Google Scholar
• Boztug H, Mühlegger N, Pötschger U, et al. Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia. Ann Hematol. 2017;96:99–106.
   PubMed Web of Science ®Google Scholar
• Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: A randomized clinical trial. JAMA. 2018;320:995–1004.
   PubMed Web of Science ®Google Scholar
• Marchant J. When antibiotics turn toxic. Nature. 2018;555:431–433.
   PubMed Web of Science ®Google Scholar
• van Vliet MJ, Tissing WJE, Dun CAJ, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis. 2009;49:262–270.
   PubMed Web of Science ®Google Scholar
• Lippi G. Sepsis biomarkers: past, present and future. Clin Chem Lab Med. 2019;57:1281–1283.
   PubMed Web of Science ®Google Scholar
• Memar MY, Baghi HB. Presepsin: A promising biomarker for the detection of bacterial infections. Biomed Pharmacother. 2019;111:649–656.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57:1308–1318.
   PubMed Web of Science ®Google Scholar
• Baraka A, Zakaria M. Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. Int J Hematol. 2018;108:184–191.
   PubMed Web of Science ®Google Scholar
• Sinha M, Jupe J, Mack H, et al. Emerging technologies for molecular diagnosis of sepsis. Clin Microbiol Rev. 2018;31:1–26.
   Web of Science ®Google Scholar
• Lehrnbecher T. Antifungal prophylaxis in pediatric patients undergoing therapy for cancer: drugs and dosing. Curr Opin Infect Dis. 2015;28:523–531.
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth european conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–e340.
   PubMed Web of Science ®Google Scholar
• Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61:393–400.
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Papachristou S, Roilides E. Advances in the treatment of mycoses in pediatric patients. J Fungi. 2018;4:1–23.
   Web of Science ®Google Scholar
• Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, et al. Voriconazole resistance and mortality in invasive aspergillosis: A multicenter retrospective cohort study. Clin Infect Dis. 2019;68:1463–1471.
   PubMed Web of Science ®Google Scholar
• Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018;67:1142–1143.
   PubMed Web of Science ®Google Scholar
• Kanamori H, Rutala WA, Sickbert-Bennett EE, et al. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015;61:433–444.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Khoo A, Tan G, et al. Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis. Antimicrob Agents Chemother. 2015;60:376–386.
   PubMed Web of Science ®Google Scholar
• Morgan JE, Hassan H, Cockle JV, et al. Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. Support Care Cancer. 2017;25:221–228.
   PubMedGoogle Scholar
• Hope WW, Castagnola E, Groll AH, et al. ESCMID* *this guideline was presented in part at ECCMID 2011. European society for clinical microbiology and infectious diseases. Guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neon. Clin Microbiol Infect. 2012;18:38–52.
   PubMed Web of Science ®Google Scholar
• Marr KA, Bow E, Chiller T, Wingard JR NMC for IB and MTRNMDPEB and MTGAS of B and MTCB and MTGI, et al. Fungal infections after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:483–487.
   PubMed Web of Science ®Google Scholar
• Ruiz-Camps I, Aguado JM, Almirante B, et al. Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish society of infectious diseases and clinical microbiology (SEIMC). Clin Microbiol Infect. 2011;17:1–24.
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Dokos C, Lehrnbecher T, et al. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Drugs. 2012;72:685–704.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Sung L. Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia. Expert Rev Hematol. 2014;7:819–830.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1–e50.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:145.
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic ma. Blood. 2000;96:2055–2061.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–1552.
   PubMed Web of Science ®Google Scholar
• Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo‐controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 2007;28:331–340.
   Google Scholar
• Fisher B, Kavcic M, Li Y, et al. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. Clin Infect Dis. 2014;58:502–508.
   PubMed Web of Science ®Google Scholar
• Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation : a systematic review and meta-analysis of randomised controlled trials. Br J Cancer. 2012;106:1626–1637.
   PubMed Web of Science ®Google Scholar
• Foot AB, Veys PA, Gibson B. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant. 1999;24:1089–1093.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials. Br J Haematol. 2005;131:22–28.
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21:4615–4626.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Döring M, Müller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012;12:1–9.
   PubMed Web of Science ®Google Scholar
• Vicenzi EB, Calore E, Decembrino N, et al. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. Eur J Haematol. 2018;100:315–322.
   PubMed Web of Science ®Google Scholar
• Molina JR, Serrano J, Sánchez-García J, et al. Voriconazole as primary antifungal prophylaxis in children undergoing. Bone Marrow Transplant. 2012;47:562–567.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59:2078–2085.
   PubMed Web of Science ®Google Scholar
• Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018;67:1142–1143.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143–147.
   PubMed Web of Science ®Google Scholar
• Van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinl Infect Dis. 2004;39:1407–1416.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Balan A, Mu L. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. J Antimicrob Chemother. 2015;70:1527–1530.
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO). Ann Hematol. 2018;97:197–207.
   PubMed Web of Science ®Google Scholar
• El Cheikh J, Dulon E, Ceballos P, et al. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: A prospective, observational study in France. Diagn Microbiol Infect Dis. 2019;94:268–273.
   PubMed Web of Science ®Google Scholar
• Epstein DJ, Seo SK, Brown JM, et al. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies. J Antimicrob Chemother. 2018;73:i60–i72.
   PubMed Web of Science ®Google Scholar
• Groll A, Castagnola E, Cesaro S, et al. Recent advances in antifungal prevention and treatment. Semin Hematol. 2009;46:212–229.
   PubMed Web of Science ®Google Scholar
• Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia : results from a randomized. Ann Oncol. 2006;17:1306–1312.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect. 2011;17:1868–1874.
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo‐controlled trial. Clin Infect Dis. 2008;46:1401–1408.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Alanio A, Cesaro S, et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients—authors’ response. J Antimicrob Chemother. 2017;73:1266–1268.
   Google Scholar
• Hughes WT, Feldman S, Aur RJ, et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–2009.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:1–8.
   PubMed Web of Science ®Google Scholar
• Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Libr. 2014;10:5–67.
   Google Scholar
• Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol. 2002;116:28–56.
   PubMed Web of Science ®Google Scholar
• Souza L, Gabrilove J, Lu H, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232:61–65.
   PubMed Web of Science ®Google Scholar
• Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012;6:CD008238.
   Web of Science ®Google Scholar
• Eds Hoffman R, Benz EJ, Shattil SJ, et al. Hematology: basic principles and practice. 2009.
   Google Scholar
• Heuser M, Zapf A, Morgan M, et al. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Ann Hematol. 2011;90:273–281.
   PubMed Web of Science ®Google Scholar
• Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the children’s oncology group. Blood. 2013;121:3573–3577.
   PubMed Web of Science ®Google Scholar
• Young C, Griffin D. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 1987;69:1771–1776.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–4506.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Creutzig U, Zimmermann M, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2006;109:936–943.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28:2591–2597.
   PubMed Web of Science ®Google Scholar
• Løhmann DJA, Asdahl PH, Abrahamsson J, et al. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. Pediatr Blood Cancer. 2019;66:e27701.
   PubMed Web of Science ®Google Scholar
• Sandherr M, Hentrich M, von Lilienfeld-toal M, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the guidelines of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO). Ann Hematol. 2015;94:1441–1450.
   PubMed Web of Science ®Google Scholar
• Licciardello M, Pegoraro A, Cesaro S. Prophylaxis and therapy of viral infections in pediatric patients treated for malignancy. Pediatr Rep. 2011;3:13–16.
   Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043–3054.
   PubMed Web of Science ®Google Scholar
• Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127:2682–2692.
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Martino R, Ward KN, et al. Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56:258–266.
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Strasfeld L, Weinstock DM. New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. Expert Opin Pharmacother. 2005;6:1669–1679.
   PubMed Web of Science ®Google Scholar
• Chen CY, Huang SY, Cheng A, et al. High risk of hepatitis B reactivation among patients with acute myeloid leukemia. PLoS One. 2015;10:1–14.
   Google Scholar
• Chen CY, Tien FM, Cheng A, et al. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterol. 2018;18:4–11.
   PubMed Web of Science ®Google Scholar